Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer

NCT00706316 | Completed Phase 1 DMC

• 1 other identifier: NPC-CTL
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Nasopharyngeal cancer (NPC) is a cancer that starts at the back of the nose. Without distant spread, NPC is sensitive to radiotherapy and chemotherapy; however, if NPC relapses or spreads to other organs, treatment options are limited. This grant proposes to evaluate the safety and tolerability of a novel treatment for patients with NPC that has either relapsed or spread to distant organs. Epstein-Barr Virus (EBV) is known to play a role in the development of NPC, and studies have shown that NPC tumor cells express proteins that are related to EBV. Some of these proteins can trigger a response from the immune system, specifically the activation of cytotoxic T lymphocytes (CTLs), a type of immune cell that might exert anti-tumor effects. In this project, we will take blood from NPC patients, generate CTLs targeted against EBV, and re-infuse these back into patients in an attempt to achieve anti-tumor activity. Patients will also receive an antibody called CD45 Mab prior to CTL infusion in order to allow for better expansion of the infused CTLs in the patients.

Conditions

Nasopharyngeal Cancer

Keywords

Nasopharygneal Cancer; Epstein Barr Virus; (EBV)-Specific Cytotoxic T-Lymphocytes; Recurrent; Metastatic; EBV-Positive Nasopharygneal Cancer

Outcome Measures

Primary Outcomes (1)

• To determine the safety of autologous EBV-specific CTLs in patients with nasopharyngeal cancer

  24 months

Secondary Outcomes (1)

• To obtain information on the expansion, persistence and anti-tumor effects of EBV-specific CTL lines in patients with nasopharyngeal cancer

  36 months

Study Arms (1)

EBV-Specific CTLs and CD45 Mab

EXPERIMENTAL

A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10\^7 cells/m2. Dose Level II: 5 x 10\^7 cells/m2. Dose Level III: 1 x 10\^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.

Biological: EBV-Specific CTLs and CD45 Mab

Interventions

EBV-Specific CTLs and CD45 Mab BIOLOGICAL

One time infusion (IV) at one of the following dose levels: Dose level I: 5 x 107 cells/m2 Dose level II: 1 x 108 cells/m2 Dose level III: 2 x 108 cells/m2

EBV-Specific CTLs and CD45 Mab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Any patient with EBV positive NPC, with recurrent and/or metastatic disease
• Patients with a life expectancy \> 3 months.
• Patients with an ECOG performance status of 0, 1 or 2
• No severe intercurrent infection.
• Patients who are able to give informed consent.
• Patients with:
• bilirubin \<2x normal,
• SGOT (AST) and SGPT (ALT) \<3x normal,
• Hgb \>80 g/L,
• absolute neutrophil count (ANC) \> 1.5 x 109/L,
• and platelets \> 100 x 109/L.
• Patients with a creatinine \<2x normal for age
• Patients should have been off any chemotherapy or other investigational therapy for at least 4 weeks prior to entry in this study.
• Patients should have completed any prior radiation therapy for at least 3 weeks prior to entry in this study. Exception may be made, however, for low-dose, non-myelosuppressive radiotherapy, but this must be discussed with Principal Investigator(s).
• All patients must have measurable disease, with minimum indicator lesions size as follows:

You may not qualify if:

• Patients with a life expectancy of \< 3 months.
• Patients with an ECOG performance status of \>2.
• Patients with a severe intercurrent infection.
• Patients unable or unwilling to give informed consent.
• Patients with a bilirubin \>2x normal.
• SGOT (AST) and SGPT (ALT) \>3x normal.
• Patients with a creatinine \>2x normal for age
• Patients with Hgb \< 80 g/L, absolute neutrophil count (ANC) \< 1.5 x 109/L, and platelets \< 100 x 109/L.
• Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. Lactating women are excluded from this study. Patients and their partners must use an effective birth control method during the study and for 6 months after. Effective birth control methods are: total abstinence, oral contraceptives, intrauterine devices, contraceptive implants under the skin or contraceptive injections. If one of these methods cannot be used, contraceptive foam with a condom is allowed. The male partner should use a condom.

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (1)

Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

Location

MeSH Terms

Conditions

Nasopharyngeal Neoplasms; Epstein-Barr Virus Infections; Recurrence; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplastic Processes

Study Officials

• Lillian Siu, MD

  University Health Network - Princess Margaret Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 25, 2008
• First Posted: June 27, 2008
• Study Start: December 1, 2007
• Primary Completion: August 1, 2009
• Study Completion: November 1, 2012
• Last Updated: July 10, 2015

Record last verified: 2015-07

Locations

CA (1)